La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !
Eris Lifesciences Gestione
Gestione criteri di controllo 4/4
Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.
Informazioni chiave
Amit Bakshi
Amministratore delegato
₹48.8m
Compenso totale
| Percentuale dello stipendio del CEO | 35.9% |
| Mandato del CEO | 17.6yrs |
| Proprietà del CEO | 42.9% |
| Durata media del management | 7.9yrs |
| Durata media del Consiglio di amministrazione | 3.8yrs |
Aggiornamenti recenti sulla gestione
Recent updates
Earnings Update: Eris Lifesciences Limited (NSE:ERIS) Just Reported Its First-Quarter Results And Analysts Are Updating Their Forecasts
Aug 05
Eris Lifesciences (NSE:ERIS) Seems To Use Debt Quite Sensibly
Aug 04Estimating The Intrinsic Value Of Eris Lifesciences Limited (NSE:ERIS)
Jul 13Eris Lifesciences Limited (NSE:ERIS) Just Reported Annual Earnings: Have Analysts Changed Their Mind On The Stock?
May 24Why We're Not Concerned About Eris Lifesciences Limited's (NSE:ERIS) Share Price
May 10An Intrinsic Calculation For Eris Lifesciences Limited (NSE:ERIS) Suggests It's 25% Undervalued
Mar 14Analyst Estimates: Here's What Brokers Think Of Eris Lifesciences Limited (NSE:ERIS) After Its Third-Quarter Report
Feb 15Earnings Tell The Story For Eris Lifesciences Limited (NSE:ERIS)
Dec 28Eris Lifesciences (NSE:ERIS) Seems To Use Debt Quite Sensibly
Dec 07Are Eris Lifesciences Limited (NSE:ERIS) Investors Paying Above The Intrinsic Value?
Nov 11Are Eris Lifesciences Limited (NSE:ERIS) Investors Paying Above The Intrinsic Value?
Jul 20Does Eris Lifesciences (NSE:ERIS) Have A Healthy Balance Sheet?
Nov 20These 4 Measures Indicate That Eris Lifesciences (NSE:ERIS) Is Using Debt Safely
Jun 20A Look At The Fair Value Of Eris Lifesciences Limited (NSE:ERIS)
Feb 24Is Now The Time To Put Eris Lifesciences (NSE:ERIS) On Your Watchlist?
Dec 28Here's Why I Think Eris Lifesciences (NSE:ERIS) Might Deserve Your Attention Today
Sep 23If You Like EPS Growth Then Check Out Eris Lifesciences (NSE:ERIS) Before It's Too Late
May 26Eris Lifesciences Limited (NSE:ERIS) Shares Could Be 34% Above Their Intrinsic Value Estimate
Apr 17Eris Lifesciences Limited's (NSE:ERIS) Stock Has Fared Decently: Is the Market Following Strong Financials?
Mar 12Does Eris Lifesciences (NSE:ERIS) Deserve A Spot On Your Watchlist?
Feb 25Why Eris Lifesciences Limited (NSE:ERIS) Is A Dividend Rockstar
Feb 12Eris Lifesciences Limited (NSE:ERIS) Analysts Are Pretty Bullish On The Stock After Recent Results
Jan 30
Read This Before Buying Eris Lifesciences Limited (NSE:ERIS) Shares
Jan 17Our View On Eris Lifesciences' (NSE:ERIS) CEO Pay
Dec 30Is Eris Lifesciences Limited's (NSE:ERIS) Recent Performance Tethered To Its Attractive Financial Prospects?
Dec 10Eris Lifesciences (NSE:ERIS) Shareholders Booked A 25% Gain In The Last Year
Nov 23Is It Worth Buying Eris Lifesciences Limited (NSE:ERIS) For Its 1.1% Dividend Yield?
Oct 22How Does Eris Lifesciences' (NSE:ERIS) CEO Salary Compare to Peers?
Oct 01How Much Are Eris Lifesciences Limited (NSE:ERIS) Insiders Taking Off The Table?
Sep 14Analisi delle retribuzioni degli amministratori delegati
| Data | Compenso totale | Stipendio | Guadagni aziendali |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | ₹4b |
| Mar 31 2024 | n/a | n/a | ₹4b |
| Dec 31 2023 | n/a | n/a | ₹4b |
| Sep 30 2023 | n/a | n/a | ₹4b |
| Jun 30 2023 | n/a | n/a | ₹4b |
| Mar 31 2023 | ₹49m | ₹17m | ₹4b |
| Dec 31 2022 | n/a | n/a | ₹4b |
| Sep 30 2022 | n/a | n/a | ₹4b |
| Jun 30 2022 | n/a | n/a | ₹4b |
| Mar 31 2022 | ₹46m | ₹26m | ₹4b |
| Dec 31 2021 | n/a | n/a | ₹4b |
| Sep 30 2021 | n/a | n/a | ₹4b |
| Jun 30 2021 | n/a | n/a | ₹4b |
| Mar 31 2021 | ₹27m | ₹27m | ₹4b |
| Dec 31 2020 | n/a | n/a | ₹3b |
| Sep 30 2020 | n/a | n/a | ₹3b |
| Jun 30 2020 | n/a | n/a | ₹3b |
| Mar 31 2020 | ₹49m | ₹18m | ₹3b |
| Dec 31 2019 | n/a | n/a | ₹3b |
| Sep 30 2019 | n/a | n/a | ₹3b |
| Jun 30 2019 | n/a | n/a | ₹3b |
| Mar 31 2019 | ₹49m | ₹18m | ₹3b |
| Dec 31 2018 | n/a | n/a | ₹3b |
| Sep 30 2018 | n/a | n/a | ₹3b |
| Jun 30 2018 | n/a | n/a | ₹3b |
| Mar 31 2018 | ₹49m | ₹11m | ₹3b |
Compensazione vs Mercato: La retribuzione totale di Amit ($USD 581.61K ) è circa la media per le aziende di dimensioni simili nel mercato Indian ($USD 473.89K ).
Compensazione vs guadagni: La retribuzione di Amit è stata coerente con le performance aziendali dell'ultimo anno.
AMMINISTRATORE DELEGATO
Amit Bakshi (48 yo)
17.6yrs
Mandato
₹48,776,648
Compensazione
Mr. Amit Indubhushan Bakshi serves as Chairman and Managing Director at Eris Lifesciences Limited. Mr. Bakshi has an extensive experience of Indian Pharmaceutical industry and handles Strategic Management...
Gruppo dirigente
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| Chairman & MD | no data | ₹48.78m | 42.87% ₹ 70.6b | |
| President | no data | ₹12.31m | Nessun dato | |
| Chief Financial Officer | 7.9yrs | ₹14.35m | Nessun dato | |
| Executive Director & COO | 3.3yrs | ₹44.85m | Nessun dato | |
| Compliance Officer & Company Secretary | 7.9yrs | Nessun dato | Nessun dato | |
| President of Sales & Marketing | no data | ₹11.24m | Nessun dato | |
| Executive Director | no data | ₹12.40m | 4.36% ₹ 7.2b | |
| Whole Time Director | no data | ₹6.99m | 3.28% ₹ 5.4b | |
| Senior Vice President | no data | ₹12.64m | Nessun dato | |
| Vice President | no data | ₹13.30m | Nessun dato | |
| Vice President | no data | ₹10.67m | Nessun dato | |
| Vice President | no data | ₹13.12m | Nessun dato |
7.9yrs
Durata media
50.5yo
Età media
Gestione esperta: Il team dirigenziale di ERIS è esperto e expertise (durata media dell'incarico 7.9 anni).
Membri del Consiglio di amministrazione
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| Chairman & MD | 17.6yrs | ₹48.78m | 42.87% ₹ 70.6b | |
| Executive Director & COO | 3.7yrs | ₹44.85m | Nessun dato | |
| Executive Director | 17.6yrs | ₹12.40m | 4.36% ₹ 7.2b | |
| Whole Time Director | 4yrs | ₹6.99m | 3.28% ₹ 5.4b | |
| Independent Director | 6.3yrs | ₹3.98m | Nessun dato | |
| Independent Director | 2.1yrs | ₹2.82m | Nessun dato | |
| Independent Director | 3.6yrs | ₹4.53m | Nessun dato | |
| Independent Director | 3.7yrs | ₹4.20m | Nessun dato |
3.8yrs
Durata media
50.5yo
Età media
Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di ERIS sono considerati esperti (durata media dell'incarico 3.8 anni).